ABSTRACT
OBJECTIVE: We describe the characterization of a new isolated in Spain of Klebsiella pneumoniae ST258 producing KPC-3, carbapenems non-susceptible, recovered from a sample of urine from a patient with urinary tract infection and no history of carbapenems exposure. METHODS: After the isolation, identification of K. pneumoniae was performed by biochemical tests and mass spectrometry. The carbapenems susceptibility testing was performed by microdilution and E-test in cation-adjusted Mueller-Hinton. The study was completed by Rapidec® Carba NP. In order to determine the genetic basis of resistance to carbapenems we used Xpert® Carba-R for carbapenemase type and subtype was subsequently analyzed by amplification by PCR and sequencing. RESULT: We demonstrated by MLST that the strain belonged to the clone of high-risk ST258. CONCLUSIONS: This is the first characterization, in our media, of a clinical isolated of K. pneumoniae ST258 producing KPC-3 and no history of carbapenems exposure.
Subject(s)
Klebsiella Infections/microbiology , Klebsiella pneumoniae , Urinary Tract Infections/microbiology , Aged, 80 and over , Bacterial Proteins/biosynthesis , Female , Humans , Klebsiella pneumoniae/enzymology , Spain , beta-Lactamases/biosynthesisABSTRACT
OBJETIVO: Presentamos la caracterización de un nuevo aislado en España de Klebsiella pneumoniae ST258 productor de KPC-3, no sensible a carbapenémicos, recuperado de una muestra de orina de una paciente con infección del tracto urinario y sin antecedentes de exposición previa a carbapenémicos. MÉTODOS: Tras el aislamiento, la identificación de K. pneumoniae fue realizada mediante pruebas bioquímicas y espectrometría de masas y la prueba de sensibilidad a carbapenémicos se realizó mediante microdilución y E-test en Mueller-Hinton ajustado para cationes. El estudio se completó mediante Rapidec® Carba NP. Con el fin de determinar las bases genéticas de la resistencia a carbapenémicos se analizó el tipo de carbapenemasa mediante Xpert® Carba-R, posteriormente se subtipo mediante amplificación por PCR y secuenciación. RESULTADO: Mediante MLST, se demostró que la cepa pertenecía al clon de alto riesgo ST258. CONCLUSIONES: Esta es la primera caracterización en nuestro medio de un aislado clínico de K. pneumoniae ST258 productor de KPC-3, sin antecedentes de exposición previa a carbapenémicos
OBJECTIVE: We describe the characterization of a new isolated in Spain of Klebsiella pneumoniae ST258 producing KPC-3, carbapenems non-susceptible, recovered from a sample of urine from a patient with urinary tract infection and no history of carbapenems exposure. METHODS: After the isolation, identification of K. pneumoniae was performed by biochemical tests and mass spectrometry. The carbapenems susceptibility testing was performed by microdilution and E-test in cation-adjusted Mueller-Hinton. The study was completed by Rapidec® Carba NP. In order to determine the genetic basis of resistance to carbapenems we used Xpert® Carba-R for carbapenemase type and subtype was subsequently analyzed by amplification by PCR and sequencing. RESULT: We demonstrated by MLST that the strain belonged to the clone of high-risk ST258. CONCLUSIONS: This is the first characterization, in our media, of a clinical isolated of K. pneumoniae ST258 producing KPC-3 and no history of carbapenems exposure
